Teva Pharmaceutical (TEVA) PriceWatch Alert For 5/21/2009 - Covered Call Risk Ranking Declines to 4 Keys
Teva Pharmaceutical (NasdaqNM: TEVA) closed yesterday at $44.70. So far the stock has hit a 52-week low of $35.89 and 52-week high of $48.74. The proprietary Key Risk Ranking for TEVA has declined from a 5 KEY Lowest Relative Risk to a 4 KEY Low Relative Risk. This Key Ranking is determined daily and is a measure of the relative risk for a conservative covered call trade on this underlying stock with a targeted 3.93% return (24.71% annualized for comparison purposes). This ranking looks at many factors related to the stock and associated option contracts. The Key ranking is intended as a guide for investors researching this underlying stock.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment